The National Institute on Aging awarded $3,391,684 under the Aging Research grant program (CFDA 93.866) to Texas A&M University Health Science Center from May 1, 2022 to April 30, 2025. The project aims to test the hypothesis that peripheral insulin-like growth factor-1 (IGF-1), delivered intraperitoneally or orally, will improve acute stroke disability as well as chronic depressive-like behaviors and cognitive impairment post-stroke in a rodent model. Researchers also expect peripheral IGF-1 to preserve the intestinal barrier and ameliorate pro-inflammatory changes to the gut microbiota and metabolites. The work is innovative in assessing long-term cognitive effects of stroke and focusing on a rodent model reflective of post-menopausal human females, a population with higher prevalence of age-related disorders. Results could provide greater understanding of extra-neural targets in mediating post-stroke dementia.
Generated 1/6/24, 6:45 PM